Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study

Tae-Hwan Kim1†, Mi Sun Ahn1†, Yong Won Choi1, Seok Yun Kang1, Jin-Hyuk Choi1, Hyun Woo Lee1*, Minae Park2 and Hasung Kim2

Abstract

Background: One-year S-1 or six-month capecitabine/oxaliplatin (CAPOX) has been the standard adjuvant chemotherapy for gastric cancer (GC). We investigated outcomes according to the cycles of adjuvant chemotherapy, using data from the Korean Health Insurance and Assessment Service.

Methods: A total of 20,552 patients, including 13,614 patients who received S-1 and 6,938 patients who received CAPOX extracted from 558,442 patients were retrospectively analyzed. The five-year overall survival rate was evaluated according to the duration of adjuvant chemotherapy.

Results: The five-year overall survival rate gradually increased according to the increase in adjuvant chemotherapy cycles in both the S-1 (≤ 5 cycles: 48.4%, hazard ratio [HR] 4.06, 95% confidence interval [CI] 3.74–4.40, P < 0.0001; 5 < cycles ≤ 6: 55.4%, HR 3.08, 95% CI 2.65–3.57, P < 0.0001; 6 < cycles ≤ 7: 64.1%, HR 2.11, 95% CI 1.84–2.41, P < 0.0001; 7 < cycles ≤ 8: 71.1%, HR 1.60, 95% CI 1.39–1.84, P < 0.0001; ≥ 8 cycles: 77.9%) and the CAPOX groups (≤ 4 cycles: 43.5%, HR 3.20, 95% CI 2.84–3.61, P < 0.0001; 5 cycles: 45.3%, HR 2.63, 95% CI 2.11–3.27, P < 0.0001; 6 cycles: 47.1%, HR 2.09, 95% CI 1.76–2.49, P < 0.0001; 7 cycles: 55.3%, HR 1.63, 95% CI 1.35–1.96, P < 0.0001; ≥ 8 cycles: 67.2%).

Conclusions: Reducing the treatment cycles of adjuvant chemotherapy in GC with S-1 or CAPOX showed inferior survival outcomes. Completing the standard duration of adjuvant chemotherapy with S-1 or CAPOX would be strongly recommended.

Keywords: Adjuvant, Chemotherapy, Gastric cancer, Survival, Nationwide cohort study
D2 lymphadenectomy has been the mainstay of standard treatment [3–7].

S-1 is an oral fluoropyrimidine derivative used for chemotherapy in various gastrointestinal malignancies [8]. After the results of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) study were published, one-year adjuvant treatment of S-1 for GC was established as a standard treatment [9, 10]. In addition, the results of the Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC) trial proved the effectiveness of an adjuvant chemotherapeutic regimen with capecitabine (i.e., an oral fluoropyrimidine carbamate) [11], and six-month therapy of capecitabine/oxaliplatin (CAPOX) has also been used as a standard treatment for GC [12].

Furthermore, a study on shortening the duration of adjuvant S-1 failed to show the noninferiority of survival outcome for six-month adjuvant chemotherapy of S-1 compared with the one-year standard treatment [9, 13].

Therefore, we aimed to examine the survival outcomes according to the duration and numbers of cycles of adjuvant chemotherapy, using the data of a large population from the Korean Health Insurance Review and Assessment Service (HIRA).

Clinical review and definition of survival outcomes
The baseline patient characteristics identified using the HIRA data were age, gender, and comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, and dyslipidemia. Because one S-1 cycle comprises a four-week treatment and a two-week rest, the S-1 cycles were identified for the prescribed days [9]. In addition, the numbers of prescriptions of oxaliplatin were confirmed for the identification of cycles in the CAPOX group.

A patient death was operationally defined as an event of follow-up loss with no clinical records or drug prescriptions for more than six months [14], because the exact date of death could not be identified using the HIRA data, furthermore, the date of death was defined as the date of the patient’s last medical record. The five-year overall survival (OS) rates were investigated from the start date of chemotherapy, while data on the survivors were censored on December 31, 2018.

Statistical analysis
The baseline characteristics according to the adjuvant chemotherapeutic regimen were compared using the Yates’s chi-squared test. The five-year OS rates were calculated using the Kaplan–Meier method. The Cox proportional hazard model was used to analyze the differences between the survival curves according to the duration of adjuvant chemotherapy. All statistical analyses were two-sided and performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).

Methods
Patients
A total of 558,442 patients were identified with the C16 code from the International Classification of Diseases in the HIRA data during the study period of January 1, 2011 until December 31, 2018. The patients who had only undergone diagnostic evaluation without treatment were excluded, which left 501,367 patients. In addition, 193,534 patients with a history of a C16 code diagnosis before the study period and 179,052 patients with no history of gastrectomy or who had a history of gastrectomy prior to the diagnosis with the C16 code were also excluded. Among the remaining 128,781 patients, we analyzed for 33,024 patients who were prescribed chemotherapeutic drugs within two months after surgery. Of these, 20,552 patients who were treated with the chemotherapeutic drug regimen of S-1 or CAPOX, which are reimbursable drugs in the Korean health insurance system, were the subjects of the final analysis, excluding the patients treated with other chemotherapeutic drugs or combination regimens with S-1 or CAPOX (Fig. 1).

The research protocol was approved by the institutional review board (IRB) of Ajou University Hospital (IRB approval no. AJIRB-MED-EXP-18–489). Informed consent was waived by the IRB because this study was conducted using the medical records of anonymized patients.

Results
Patient characteristics
A total of 20,552 patients were analyzed: 13,614 patients who received S-1 and 6,938 patients who received CAPOX. Of these, 4,676 patients (S-1: 3,137 patients, CAPOX: 1,539 patients) were concluded to have died according to the operational definition. The most common durations of follow-up loss for patients defined as having died were 1–2 years (S-1: 746 patients [23.8%]; CAPOX: 411 patients [26.7%]) and 2–3 years (S-1: 554 patients [17.7%]; CAPOX: 347 patients [22.5%]). The numbers of the patients with duration of follow-up loss between six months and one year were 591 patients (18.8%) for S-1 and 301 patients (19.6%) for CAPOX, respectively.

The patient characteristics are summarized in Table 1. The mean age was 61.4 years, and patients aged in their 50 s, 60 s and 70 s accounted for the largest proportions: 25.5%, 28.5%, and 24.9%, respectively. Male patients predominated (N = 14,063; 68.4%).

The numbers of patients with diabetes mellitus, hypertension, dyslipidemia, or chronic obstructive pulmonary
disease were 4,772 (23.2%), 8,133 (39.6%), 2,143 (10.4%), or 6,712 (32.7%), respectively. All comorbidities were significantly more common in the S-1 group (Table 1).

The patients who completed eight cycles of adjuvant chemotherapy were most common in both the S-1 and CAPOX groups (S-1: 50.9%; CAPOX: 60.0%). The patients who received S-1 for five cycles or fewer and CAPOX for four cycles or fewer were second most common (S-1: 28.7%; CAPOX: 20.4%). The proportions of patients treated with other cycles of adjuvant chemotherapy are shown in Table 2 and Table 3.

**Patient outcomes**

With a median follow-up duration of 2.3 years, the five-year OS rates were 68.2% for the patients treated with S-1 and 60.9% for the patients treated with CAPOX (Fig. 2).

---

**Fig. 1** Study design. ICD indicates the International Classification of Diseases.
### Table 1  Patient characteristics

| Clinical characteristics          | Total (N = 20,552) | S-1 (N = 13,614) | Capecitabine/oxaliplatin (N = 6,938) | P Value |
|-----------------------------------|--------------------|-----------------|-------------------------------------|---------|
| Age, years, mean (SD)             | 61.4 (12.0)        | 63.3 (12.1)     | 57.6 (11.0)                         | <0.0001 |
| Age group, years, N (%)           |                    |                 |                                     |         |
| < 30                              | 101 (0.5)          | 53 (0.4)        | 48 (0.7)                            | <0.0001 |
| 30–39                             | 826 (4.0)          | 447 (3.3)       | 379 (5.5)                           |         |
| 40–49                             | 2,541 (12.4)       | 1,417 (10.4)    | 1,124 (16.2)                        |         |
| 50–59                             | 5,231 (25.5)       | 2,980 (21.9)    | 2,251 (32.4)                        |         |
| 60–69                             | 5,866 (28.5)       | 3,759 (27.6)    | 2,107 (30.4)                        |         |
| 70–79                             | 5,126 (24.9)       | 4,166 (30.6)    | 960 (13.8)                          |         |
| ≥ 80                              | 861 (4.2)          | 792 (5.8)       | 69 (1.0)                            |         |
| Gender, N (%)                     |                    |                 |                                     |         |
| Male                              | 14,063 (68.4)      | 9,226 (67.8)    | 4,837 (69.7)                        | 0.0047  |
| Female                            | 6,489 (31.6)       | 4,388 (32.2)    | 2,101 (30.3)                        |         |
| Comorbidities, N (%)              |                    |                 |                                     |         |
| DM                                | 4,772 (23.2)       | 3,360 (24.7)    | 1,412 (20.4)                        | <0.0001 |
| Hypertension                      | 8,133 (39.6)       | 5,803 (42.6)    | 2,330 (33.6)                        | <0.0001 |
| Dyslipidemia                      | 2,143 (10.4)       | 1,561 (11.5)    | 582 (8.4)                           | <0.0001 |
| COPD                              | 6,712 (32.7)       | 4,535 (33.3)    | 2,177 (31.4)                        | 0.0055  |

**Abbreviations: SD Standard deviation, DM Diabetes mellitus, COPD Chronic obstructive pulmonary disease**

### Table 2  Univariate and multivariate analyses about survival outcomes in the patients treated with S-1

| Characteristics          | Total 13,614 (100.0) | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
|--------------------------|-----------------------|------------------------|---------|----------------------|---------|
| Age, years               | < 30                  | 53 (0.4)               | 1       |                      | 1       |
|                          | 30–39                 | 447 (3.3)              | 0.71 (0.41–1.21) | 0.207 | 0.69 (0.40–1.18) | 0.172 |
|                          | 40–49                 | 1,417 (10.4)           | 0.54 (0.32–0.91) | 0.021 | 0.53 (0.31–0.89) | 0.016 |
|                          | 50–59                 | 2,980 (21.9)           | 0.61 (0.36–1.01) | 0.057 | 0.57 (0.34–0.95) | 0.032 |
|                          | 60–69                 | 3,759 (27.6)           | 0.76 (0.46–1.27) | 0.294 | 0.70 (0.42–1.17) | 0.173 |
|                          | 70–79                 | 4,166 (30.6)           | 1.18 (0.71–1.96) | 0.528 | 0.95 (0.57–1.58) | 0.834 |
|                          | ≥ 80                  | 792 (5.8)              | 2.10 (1.25–3.53) | 0.005 | 1.44 (0.85–2.43) | 0.175 |
| Gender                   | Male                  | 9,226 (67.8)           | 1       |                      | 1       |
|                          | Female                | 4,388 (32.2)           | 0.86 (0.80–0.93) | 0.0002 | 0.83 (0.77–0.90) | <0.0001 |
| Comorbidities            | DM                    | 10,254 (75.3)          | 1       |                      | 1       |
|                          | Yes                   | 3,360 (24.7)           | 1.25 (1.16–1.36) | <0.0001 | 1.11 (1.01–1.21) | 0.03  |
|                          | No                    | 7,811 (57.4)           | 1       |                      | 1       |
| Hypertension             | Yes                   | 5,803 (42.6)           | 1.16 (1.08–1.25) | <0.0001 | 0.89 (0.82–0.96) | 0.004 |
|                          | No                    | 9,079 (66.7)           | 1       |                      | 1       |
| Dyslipidemia             | Yes                   | 4,535 (33.3)           | 1.04 (0.97–1.13) | 0.292 | 0.96 (0.88–1.05) | 0.375 |
|                          | No                    | 12,053 (88.5)          | 1       |                      | 1       |
| COPD                     | Yes                   | 1,561 (11.5)           | 1.19 (1.07–1.33) | 0.002 | 0.99 (0.89–1.10) | 0.839 |
| Chemotherapy cycles      | ≥ 8 cycles            | 6,930 (50.9)           | 1       |                      | 1       |
|                          | 7 < cycles ≤ 8        | 1,071 (7.9)           | 1.60 (1.39–1.84) | <0.0001 | 1.54 (1.34–1.78) | <0.0001 |
|                          | 6 < cycles ≤ 7        | 990 (7.3)              | 2.11 (1.84–2.41) | <0.0001 | 2.03 (1.78–2.32) | <0.0001 |
|                          | 5 < cycles ≤ 6        | 709 (5.2)              | 3.08 (2.65–3.57) | <0.0001 | 2.86 (2.47–3.32) | <0.0001 |
|                          | ≤ 5 cycles            | 3,914 (28.7)           | 4.06 (3.74–4.40) | <0.0001 | 3.64 (3.35–3.95) | <0.0001 |

**Abbreviations: HR Hazard ratio, CI Confidence interval, DM Diabetes mellitus, COPD Chronic obstructive pulmonary disease**
Table 3  Univariate and multivariate analyses about survival outcomes in the patients treated with capecitabine/oxaliplatin

| Characteristics         | Number of patients (%) | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
|-------------------------|------------------------|------------------------|---------|----------------------|---------|
| Total                   | 6,938 (100.0)          |                        |         |                      |         |
| Age, years              |                        |                        |         |                      |         |
| < 30                    | 48 (0.7)               | 1                      | 1       | 1                    | 1       |
| 30–39                   | 379 (5.5)              | 0.77 (0.45–1.33)       | 0.353   | 0.89 (0.52–1.54)     | 0.680   |
| 40–49                   | 1,124 (16.2)           | 0.77 (0.46–1.30)       | 0.324   | 0.91 (0.54–1.53)     | 0.724   |
| 50–59                   | 2,251 (32.4)           | 0.69 (0.41–1.15)       | 0.156   | 0.81 (0.49–1.36)     | 0.431   |
| 60–69                   | 2,107 (30.4)           | 0.71 (0.43–1.19)       | 0.197   | 0.83 (0.50–1.40)     | 0.491   |
| 70–79                   | 960 (13.8)             | 0.88 (0.52–1.49)       | 0.637   | 0.92 (0.54–1.56)     | 0.764   |
| ≥ 80                    | 69 (1.0)               | 1.57 (0.82–3.01)       | 0.174   | 1.37 (0.71–2.66)     | 0.346   |
| Gender                  |                        |                        |         |                      |         |
| Male                    | 4,837 (69.7)           | 1                      | 1       | 1                    | 1       |
| Female                  | 2,101 (30.3)           | 1.05 (0.94–1.17)       | 0.38    | 1.00 (0.90–1.12)     | 0.992   |
| Comorbidities           |                        |                        |         |                      |         |
| DM                      |                        |                        |         |                      |         |
| No                      | 5,526 (79.6)           | 1                      | 1       | 1                    | 1       |
| Yes                     | 1,412 (20.4)           | 1.01 (0.90–1.15)       | 0.828   | 1.02 (0.89–1.17)     | 0.767   |
| Hypertension            |                        |                        |         |                      |         |
| No                      | 4,608 (66.4)           | 1                      | 1       | 1                    | 1       |
| Yes                     | 2,330 (33.3)           | 0.94 (0.85–1.05)       | 0.271   | 0.92 (0.81–1.04)     | 0.183   |
| Dyslipidemia            |                        |                        |         |                      |         |
| No                      | 4,761 (68.6)           | 1                      | 1       | 1                    | 1       |
| Yes                     | 2,177 (31.4)           | 0.95 (0.85–1.07)       | 0.398   | 0.96 (0.84–1.08)     | 0.471   |
| COPD                    |                        |                        |         |                      |         |
| No                      | 6,356 (91.6)           | 1                      | 1       | 1                    | 1       |
| Yes                     | 582 (8.4)              | 1.06 (0.88–1.27)       | 0.535   | 0.97 (0.80–1.16)     | 0.702   |
| Chemotherapy cycles     | ≥ 8 cycles             | 4,161 (59.9)           | 1       | 1                    | 1       |
| 7 < cycles < 8          | 514 (7.4)              | 1.63 (1.35–1.96)       | < 0.0001| 1.63 (1.35–1.97)     | < 0.0001|
| 6 < cycles ≤ 7          | 531 (7.7)              | 2.09 (1.76–2.49)       | < 0.0001| 2.10 (1.76–2.49)     | < 0.0001|
| 5 < cycles ≤ 6          | 317 (4.6)              | 2.63 (2.11–3.27)       | < 0.0001| 2.61 (2.10–3.26)     | < 0.0001|
| ≤ 5 cycles              | 1,415 (20.4)           | 3.20 (2.84–3.61)       | < 0.0001| 3.16 (2.79–3.57)     | < 0.0001|

Abbreviations: HR Hazard ratio, CI Confidence interval, DM Diabetes mellitus, COPD Chronic obstructive pulmonary disease

Fig. 2  Overall survival rates according to the adjuvant chemotherapeutic regimen. CAPOX indicates capecitabine/oxaliplatin.
Both the S-1 and CAPOX groups showed statistically significant increases in five-year OS rates as the number of cycles of adjuvant chemotherapy increased. In the patients who received S-1, the five-year OS rates gradually increased from 48.4% to 55.4%, 64.1%, 71.1%, and 77.9% as the number of adjuvant chemotherapy cycles increased from five cycles or fewer to eight cycles or more, respectively ($P<0.0001$). In addition, the same trend was identified in the patients with CAPOX from four cycles or fewer to eight cycles or more: 43.5%, 45.3%, 47.1%, 55.3%, and 67.2%, respectively ($P<0.0001$) (Tables 2, and 3, and Fig. 3).

**Discussion**

GC is one of the most common causes of cancer-related mortality worldwide [15, 16]. Since the results of the ACTS-GC and CLASSIC trials were published, one-year S-1 and six-month CAPOX adjuvant chemotherapy have been widely used in real-world practice. Surgery followed by adjuvant chemotherapy has generally been the standard treatment for locally advanced GC in Korea, because D2 lymph node dissection has been considered the standard procedure in East Asia, in contrast to Western Europe [17–20]. Therefore, those chemotherapeutic regimens have been reimbursable in the Korean national health insurance system, and we investigated the clinical outcomes of the adjuvant regimens in this real-world big data analysis.

In this study, the five-year OS rates for the patients who received CAPOX were poorer than those for the patients who were treated with S-1. We assumed that there were more patients with stage III GC in the CAPOX group because the S-1 adjuvant chemotherapy patients showed relatively poor survival outcomes for stage III [9, 21]. Although this study was a big data analysis, making it difficult to know the exact stage of the patients, it is estimated that the patients who received adjuvant treatment of CAPOX had a higher proportion of more advanced disease.

Our results showed that both the S-1 and the CAPOX groups had significantly better five-year OS rates as the number of cycles of adjuvant chemotherapy increased. A previous study was conducted to reduce the duration of adjuvant chemotherapy with a six-month S-1 regimen. However, that study showed poorer survival outcomes compared to the standard one-year treatment with S-1 [13]. Using a big data analysis of a larger populations in the real world, the current study showed equivalent results to the previous study. As a result, we recommend the completion of adjuvant chemotherapy with one-year S-1 or six-month CAPOX for GC as possible.

This study has some limitations. First, this was a retrospective study, and the study results cannot be generalized. Therefore, prospective studies will be needed. Second, this study was a big data analysis, and OS was operationally defined, because it was impossible to accurately identify the patients’ dates of death. Third, it is possible that a very small number of GC patients with stage IV who were treated with S-1 or CAPOX as palliative chemotherapy after palliative gastrectomy were included due to a limitation of HIRA database that does not provide the information of disease stage, which would have acted as an obstacle to more accurate analysis. Fourth, death was operationally defined as an event of follow-up...
loss with no clinical records or drug prescriptions for more than six months, which was likely to include some live patients. However, the proportion of patients with no clinical records between six months and one year was less than 20%, and most of the patients were those with no clinical records for more than one year. Fifth, D1 or D2 dissection, exact pathologic stage of GC patients in this study, or cause of decrease in cycles of adjuvant chemotherapy for each patient could not be identified as a limitation of Korean HIRA database. Sixth, Nonetheless, the five-year OS rates of this study results were comparable to those of the ACTS-GC and CLASSIC trials, considering that the patients who did not complete the standard duration of adjuvant chemotherapy were included [9, 22]. Therefore, it could be considered that sufficient trends were reflected. Despite some limitations, this study has great significance in demonstrating the benefits of adjuvant chemotherapy of one-year S-1 and six-month CAPOX through a real-world big data analysis.

**Conclusion**

Reducing the treatment cycles of adjuvant chemotherapy in GC with S-1 or CAPOX showed inferior survival outcomes in a real-world big data analysis and completing the standard duration of adjuvant chemotherapy with S-1 or CAPOX would be strongly recommended.

**Availability data and materials**

The datasets generated and/or analyzed during the current study are not publicly available due to the confidentiality of the data of patient but are available from the corresponding author on reasonable request.

**Abbreviations**

GC: Gastric cancer; ACTS-GC: Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer; CLASSIC: Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer; CAPOX: Capecitabine/oxaliplatin; HIRA: Health insurance review and assessment service; IRB: Institutional review board; OS: Overall survival.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

THK, MSA, HWL, MP and HK designed and planned the study. THK, MSA, YWC, SYK, JHC and HWL collected and analyzed clinical data. THK and MSA wrote the main manuscript and THK, MSA and HWL edited the manuscript. THK, MSA and HWL performed statistical analysis, and MP and HK reviewed the statistical analysis. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

This study was conducted in accordance with the principles expressed in the Declaration of Helsinki. The study protocols were approved by the institutional review board of Ajou University Hospital (IRB approval no. AJIRB-MED-EXP-18-489). Furthermore, the institutional review board of Ajou University Hospital decided to waive the informed consent for this study because it was a retrospective study using anonymized data.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**Author details**

1Department of Hematology-Oncology, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon 16499, Gyeonggi-do, Korea. 2Data Science Team, Hanmi Pharm. Co. Ltd, Seoul, Korea.

**Received:** 14 June 2022  **Accepted:** 16 August 2022  **Published online:** 03 September 2022

**References**

1. Jung KW, Won YJ, Kong HU, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019;51(2):417–30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019;51(2):417–30.
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):1–20.
4. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin vs epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLATO-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.
5. Al-Batran SE, Hohenberger W, Pauligk C, Illerhaus G, Martens U, Stoehlmaier J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLATO trial. JAMA Oncol. 2017;3(9):1237–44.
6. Bracale U, Coricione F, Pignata G, Andreuccetti J, Dolce P, Boni L, et al. Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: A multi-institutional propensity score-matched study. J Surg Oncol. 2021;124(8):1338–46.
7. Bracale U, Merola G, Pignata G, Andreuccetti J, Dolce P, Boni L, et al. Laparoscopic gastrectomy for stage II and III advanced gastric cancer: long-term follow-up data from a Western multicenter retrospective study. Surg Endosc. 2022;36(4):2300–11.
8. Maehara Y, S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6(Suppl 1):2–8.
9. Sasako M, Sakuramoto S, Katai H, Kinoshita H, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujiy, Nishimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.
11. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates S-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8):1274–81.
12. Noh SH, Park SR, Yang HK, Chung HC, Chung UJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.
13. Yoshikawa T, Terasima M, Mizusawa J, Nuncobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase
3. non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(3):208–16.

14. Lee JS, Hong JH, Sun S, Won HS, Kim YH, Ahn MS, et al. The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: a retrospective nationwide population-based cohort study. Sci Rep. 2019;9(1):18689.

15. G. B. D. Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):42–54.

16. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

17. Degiuli M, De Manzoni G, Di Leo A, D’Ugo D, Galasso E, Marrelli D, et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol. 2016;22(10):2875–93.

18. Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745.

19. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Krannenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.

20. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer. 1999;79(9–10):1522–30.

21. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.

22. Noh SH, Park SR, Yang HK, Chung HC, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.